Characteristics and treatment patterns among us patients with hairy cell leukemia: A retrospective Claims analysis

Journal of Comparative Effectiveness Research

Volumn 6, Issue 6, 2017, Pages 497-508

  Divino, Victoria ^a   Karve, Sudeep ^b   Gaughan, Andrew ^b   Dekoven, Mitch ^a   Gao, Guozhi ^c   Knopf, Kevin B ^d   Lanasa, Mark C ^c  

^a IQVIA   (United States)

^b ASTRAZENECA   (United Kingdom)

^c MEDIMMUNE   (United States)

^d SUTTER HEALTH   (United States)

Author keywords

Hairy cell leukemia; Retrospective studies; Treatment utilization

Indexed keywords

ALPHA2B INTERFERON; CLADRIBINE; IMATINIB; METHOTREXATE; PENTOSTATIN; PURINE NUCLEOSIDE DERIVATIVE; ANTINEOPLASTIC AGENT; RITUXIMAB;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER THERAPY; DATA BASE; DEMOGRAPHY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GEOGRAPHIC DISTRIBUTION; HAIRY CELL LEUKEMIA; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SECONDARY HEALTH CARE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; CLINICAL TRIAL; FACTUAL DATABASE; HOSPITALIZATION; INSURANCE; MIDDLE AGED; MULTICENTER STUDY; REMISSION; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA;

ANTINEOPLASTIC AGENTS; CLADRIBINE; DATABASES, FACTUAL; FEMALE; HOSPITALIZATION; HUMANS; INSURANCE CLAIM REVIEW; LEUKEMIA, HAIRY CELL; MALE; METHOTREXATE; MIDDLE AGED; PENTOSTATIN; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RITUXIMAB; TREATMENT OUTCOME;

EID: 85032742501     PISSN: 20426305     EISSN: 20426313     Source Type: Journal    
DOI: 10.2217/cer-2017-0014     Document Type: Article

References (22)

1. Grever MR, Blachly JS, Andritsos LA. Hairy cell leukemia: update on molecular profiling and therapeutic advances. Blood Rev. 28, 197-203 (2014).
2. Grever MR. How I treat hairy cell leukemia. Blood 115, 21-28 (2010).
3. Maevis V, Mey U, Schmidt-Wolf G, Schmidt-Wolf IG. Hairy cell leukemia: short review, today's recommendations and outlook. Blood Cancer J. 4, e184 (2014).
4. NCCN Clinical Practice Guidelines in Oncology: Hairy Cell Leukemia. National Comprehensive Cancer Network (2017). https://www.nccn.org/professionals/physician-gls
5. Robak T, Matutes E, Catovsky D, Zinzani PL, Buske C. ESMO Guidelines Committee. Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 26(Suppl. 5), v100-v107 (2015).
6. Grever MR, Abdel-Wahab O, Andritsos LA et al. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood 129, 553-560 (2017).
7. Dearden CE, Else M, Catovsky D. Long-term results for pentostatin and cladribine treatment of hairy cell leukemia. Leuk. Lymphoma 52, 21-24 (2011).
8. Else M, Dearden CE, Matutes E et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br. J. Haematol. 145, 733-740 (2009).
9. Jain P, Pemmaraju N, Ravandi F. Update on the biology and treatment options for hairy cell leukemia. Curr. Treat. Options Oncol. 15, 187-209 (2014).
10. Maloisel F, Benboubker L, Gardembas M et al. Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients. Leukemia 17, 45-51 (2003).
11. Saven A, Burian C, Koziol JA, Piro LD. Long-term followup of patients with hairy cell leukemia after cladribine treatment. Blood 92, 1918-1926 (1998).
12. Naik RR, Saven A. My treatment approach to hairy cell leukemia. Mayo Clin. Proc. 87, 67-76 (2012).
13. Zinzani PL, Pellegrini C, Stefoni V et al. Hairy cell leukemia: evaluation of the long-term outcome in 121 patients. Cancer 116, 4788-4792 (2010).
14. Cornet E, Tomowiak C, Tanguy-Schmidt A et al. Long-term follow-up and second malignancies in 487 patients with hairy cell leukaemia. Br. J. Haematol. 166, 390-400 (2014).
15. López Rubio M, Da Silva C, Loscertales J et al. Hairy cell leukemia treated initially with purine analogs: a retrospective study of 107 patients from the Spanish Cooperative Group on Chronic Lymphocytic Leukemia (GELLC). Leuk. Lymphoma 55, 1007-1012 (2014).
16. Giri S, Shrestha R, Pathak R, Bhatt VR. Racial differences in the overall survival of hairy cell leukemia in the United States: a population-based analysis of the Surveillance, Epidemiology, and End Results database. Clin. Lymphoma Myeloma Leuk. 15, 484-488 (2015).
17. Chandran R, Gardiner SK, Smith SD, Spurgeon SE. Improved survival in hairy cell leukaemia over three decades: a SEER database analysis of prognostic factors. Br. J. Haematol. 163, 407-409 (2013).
18. Anderson LA, Engels EA. Autoimmune conditions and hairy cell leukemia: an exploratory case-control study. J. Hematol. Oncol. 3, 35 (2010).
19. Rosenberg JD, Burian C, Waalen J, Saven A. Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series. Blood 123, 177-183 (2014).
20. Chastek B, Kulakodlu M, Valluri S, Seal B. Impact of metastatic colorectal cancer stage and number of treatment courses on patient health care costs and utilization. Postgrad. Med. 125, 73-82 (2013).
21. Song X, Zhao Z, Barber B, Gregory C, Wang PF, Long SR. Treatment patterns and metastasectomy among mCRC patients receiving chemotherapy and biologics. Curr. Med. Res. Opin. 27, 123-130 (2011).
22. Hess GP, Wang PF, Quach D, Barber B, Zhao Z. Systemic therapy for metastatic colorectal cancer: patterns of chemotherapy and biologic therapy use in US medical oncology practice. J. Oncol. Pract. 6, 301-307 (2010).